Human recombinant glutamate oxaloacetate transaminase 1 (GOT1) supplemented with oxaloacetate induces a protective effect after cerebral ischemia

Cell Death and Disease

Volumn 5, Issue 1, 2014, Pages

  Perez Mato M ^a   Ramos Cabrer, P ^a   Sobrino, T ^a   Blanco, M ^a   Ruban, A ^b   Mirelman, D ^b   Menendez, P ^c,d   Castillo, J ^a   Campos, F ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Animal model; Cerebral ischemia; Glutamate; GOT; Neuroprotection; Oxaloacetate

Indexed keywords

ASPARTATE AMINOTRANSFERASE ISOENZYME 1; GLUTAMIC ACID; OXALOACETIC ACID; RECOMBINANT ASPARTATE AMINOTRANSFERASE ISOENZYME 1; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME THERAPY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MONOTHERAPY; NEUROIMAGING; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SENSORIMOTOR FUNCTION; THERAPY DELAY; TOXICITY TESTING;

ANIMALS; ASPARTATE AMINOTRANSFERASE, CYTOPLASMIC; BRAIN; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; HUMANS; MALE; OXALOACETIC ACID; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84891773306     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.507     Document Type: Article

References (20)

1. Tomsick TA, Khatri P, Jovin T, Demaerschalk B, Malisch T, Demchuk A et al. Equipoise among recanalization strategies. Neurology 2010; 74: 1069-1076.
2. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999; 79: 1431-1568.
3. Ginsberg MD. Neuroprotection for ischemic stroke: past present and future. Neuropharmacology 2008; 55: 363-389.
4. Teichberg VI, Cohen-Kashi-Malina K, Cooper I, Zlotnik A. Homeostasis of glutamate in brain fluids: an accelerated brain-to-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuropathologies. Neuroscience 2009; 158: 301-308.
5. Campos F, Sobrino T, Ramos-Cabrer P, Castillo J. Oxaloacetate: a novel neuroprotective for acute ischemic stroke. Int J Biochem Cell Biol 2012; 44: 262-265.
6. Campos F, Sobrino T, Ramos-Cabrer P, Argibay B, Agulla J, Perez-Mato M et al. Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study. J Cereb Blood Flow Metab 2011; 31: 1378-1386.
7. Leibowitz A, Boyko M, Shapira Y, Zlotnik A. Blood glutamate scavenging: insight into neuroprotection. Int J Mol Sci 2012; 13: 10041-10066.
8. Campos F, Rodriguez-Yanez M, Castellanos M, Arias S, Perez-Mato M, Sobrino T et al. Blood levels of glutamate oxaloacetate transaminase are more strongly associated with good outcome in acute ischaemic stroke than glutamate pyruvate transaminase levels. Clin Sci (Lond) 2011; 121: 11-17.
9. Campos F, Sobrino T, Ramos-Cabrer P, Castellanos M, Blanco M, Rodriguez-Yanez M et al. High blood glutamate oxaloacetate transaminase levels are associated with good functional outcome in acute ischemic stroke. J Cereb Blood Flow Metab 2011; 31: 1387-1393.
10. Llorens J, Li AA, Ceccatelli S, Sunol C. Strategies and tools for preventing neurotoxicity: to test, to predict and how to do it. Neurotoxicology 2012; 33: 796-804.
11. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999; 30: 2752-2758.
12. Ruban A, Berkutzki T, Cooper I, Mohar B, Teichberg VI. Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas. Invest New Drugs 2012; 30: 2226-2235.
13. Tian Z, Liu H, Su X, Fang Z, Dong Z, Yu C et al. Role of elevated liver transaminase levels in the diagnosis of liver injury after blunt abdominal trauma. Exp Ther Med 2012; 4: 255-260.
14. Yoshikawa K. Studies on the anti-diabetic effect of sodium oxaloacetate. Tohoku J Exp Med 1968; 96: 127-141.
15. Zlotnik A, Gruenbaum SE, Artru AA, Rozet I, Dubilet M, Tkachov S et al. The neuroprotective effects of oxaloacetate in closed head injury in rats is mediated by its blood glutamate scavenging activity: evidence from the use of maleate. J Neurosurg Anesthesiol 2009; 21: 235-241.
16. Philip M, Benatar M, Fisher M, Savitz SI. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke 2009; 40: 577-581.
17. Higuchi T, Graham SH, Fernandez EJ, Rooney WD, Gaspary HL, Weiner MW et al. Effects of severe global ischemia on N-acetylaspartate and other metabolites in the rat brain. Magn Reson Med 1997; 37: 851-857.
18. Tkac I, Starcuk Z, Choi IY, Gruetter R. In vivo 1 H NMR spectroscopy of rat brain at 1ms echo time. Magn Reson Med 1999; 41: 649-656.
19. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000; 39: 777-787.
20. Moro MA, Fernandez-Tome P, Leza JC, Lorenzo P, Lizasoain I. Neuronal death induced by SIN-1 in the presence of superoxide dismutase: protection by cyclic GMP. Neuropharmacology 1998; 37: 1071-1079.